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Vitamin B1 (thiamine) is an essential nutrient that acts as a cofactor for a number of metabolic processes, partic-
ularly in energy metabolism. Symptoms of classic thiamine deficiency are recognized as beriberi, although clinical
symptoms are nonspecific and recognition of subclinical deficiency is difficult. Therefore, reliable biomarkers of
thiamine status are required. Thiamine diphosphate is a cofactor for transketolase, including erythrocyte transke-
tolase (ETK). The ETK activity assay as an indirect, functional marker of thiamine status has been used for over
50 years. The ETK activity assay provides a sensitive and specific biomarker of thiamine status; however, there is
a lack of consensus over the cutoffs for deficiency, partly due to a lack of assay harmonization. Here, we provide
a step-by-step protocol for the measurement of ETK activity and the calculation of the ETK activity coefficient,
including detailed explanations of equipment and chemicals required and guidance for quality control procedures.
Harmonization of the protocol will provide the basis for the development of internationally recognized cutoffs for
thiamine insufficiency. The establishment of quality control materials and a quality assurance scheme are recom-
mended to provide reliability. This will ensure that the ETK activity assay remains an important method for the
assessment of thiamine status.
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Introduction
Thiamine (vitamin B1) is an essential micronutri-
ent. In humans, the majority of thiamine exists in
phosphorylated forms: thiamine monophosphate,
thiamine diphosphate (ThDP) (also known as thi-
amine pyrophosphate), and thiamine triphosphate.
ThDP is the major form, making up around 80% of
total blood thiamine and is mainly present in ery-
throcytes and white blood cells.
ThDP is an essential cofactor for a number
of metabolic enzymes, particularly those associ-
ated with oxidative and nonoxidative carbohydrate
metabolism. These include pyruvate dehydroge-
nase (responsible for the conversion of pyruvate
to acetyl-coenzyme A), α-ketoglutarate dehydroge-
nase in the Krebs cycle, and the branched chain
α-keto acid dehydrogenase complex. In nonoxida-
tive carbohydrate metabolism, ThDP is a cofactor
for the transketolase in the pentose phosphate path-
way, necessary for the production of pentoses and
NADPH used in nucleic acid and fatty acid synthe-
sis, respectively.1
Thiamine deficiency is associated with nonspe-
cific clinical symptoms affecting the cardiovascular,
muscular, and nervous systems. The classical man-
ifestation of thiamine deficiency is beriberi. The
populations most at risk are breastfed infants of
thiamine-deficient mothers in low-income coun-
tries, particularly those with poor diet diversity and
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where rice is the staple food.2,3 In high-income
countries, deficiency is rare but may be present in
the elderly, chronic alcoholics, and persons with
acute or chronic medical conditions associated with
malnutrition.1 In addition to the effect of acute defi-
ciency, evidence also exists that subclinical defi-
ciency may have long-term effects on cognition and
gross motor skills.2
In order to investigate the potential impact of
subclinical deficiency and to improve our under-
standing of the global prevalence of thiamine defi-
ciency, biomarkers to assess thiamine status are
essential. Themeasurement of serum or plasma thi-
amine concentration is of limited use since it rep-
resents only a small portion of thiamine in the
blood and is affected by a number of disease states.1
Although a correlation between plasma thiamine
and erythrocyte ThDP has been shown,4 these data
were from a thiamine fortification trial; plasma thi-
amine is affected by recent dietary intake and is,
therefore, not suitable as a biomarker of long-term
thiamine status. Urinary thiamine excretion may
correlate with all levels of thiamine intake but low
intakes. However, it does not provide information
on thiamine status, particularly when status is low,
as thiamine may be conserved. In addition, single
24-h urine collections are of limited use due to large
within-subject variability.5 Longer-term thiamine
status from human blood samples can be assessed
either by direct measurement of ThDP in erythro-
cytes or whole blood, or by the measurement of
the degree of ThDP-saturation of erythrocyte trans-
ketolase (ETK), a ThDP-dependent enzyme. The
advantages and disadvantages of both the direct and
indirect assays were reviewed recently,1,2,6 including
a detailed description of the direct measurement of
ThDP. However, the methodology to measure ETK
activity has received less attention.
ETK activity is commonly expressed as a ratio or
“activity coefficient” (ETKAC). Two measurements
are made to determine the EKTAC: (1) the basal
activity of ETK and (2) “activated” or “stimulated”
ETK activity by the addition of exogenous excess
ThDP. The ratio of activated to basal activity gives
the ETKAC and provides a proxymeasure for the in
vivo activity of ETK and an indication of the avail-
ability of ThDP and thiamine status.
In this manuscript, we describe the background
to the ETK activation assay and discuss aspects
relating to reliability and robustly performing,
reporting, and interpreting the ETK activity data.
In addition, we present a step-by-step protocol (see
File S1, online only) that provides detailed guidance
and should enable laboratories to set up the method
independently and improve harmonization.
Historical background
The ETK activity assay in its early form for the
application of thiamine deficiency assessment was
established by Brin7 and was later improved and
adapted as understanding and technology pro-
gressed. Assays moved from the less specific col-
orimetric determination of substrate disappearance
or appearance of end products to UV detection
of NADH.8 The assay relies on the detection of
small changes in enzyme activity and early methods
lacked the necessary sensitivity and had relatively
poor precision. The assay was further refined and
adapted for semiautomated clinical chemistry ana-
lyzers. This improved measurement precision, even
at observed high absorbance, and the ability to run
basal and activated measurements side by side fur-
ther improved performance.9,10 For additional con-
venience and to remove the need for large, expen-
sive equipment, the assay has been further adapted
to a 96-well plate format and measurement with a
plate reader.11 The assay as it is currently performed
in our laboratory is described herein.
Chemistry of the assay
The ThDP-dependent enzyme ETK catalyzes the
metabolism of pentoses in two reactions in the pen-
tose phosphate pathway:
(1) xylulose-5-phosphate + ribose-5-phosphate 
sedoheptulose-7-phosphate + glyceraldehyde-3-
phosphate
(2) xylulose-5-phosphate + erthyose-4-phosphate
 fructose-6-phosphate + glyceraldehyde-3-
phosphate
In the current assay, the resultant glyceraldehyde-
3-phosphate is metabolized to dihydroxyacetone
phosphate, which in the final reaction is reduced
to glycerol-3-phosphate by glycerol-3-phosphate
dehydrogenase andNADH (Fig. 1). The assaymon-
itors the rate of oxidation of NADH by measuring
the decrease in absorbance at 340 nanometers. In
the described protocol, xylulose-5-phosphate is not
required as a substrate; ribose-5-phosphate is con-
verted to xylulose-5-phosphate by the erythrocyte
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Figure 1. The enzymatic reactions in the ETK activity assay. The assay monitors the decrease in absorbance at 340 nm related to
NADH oxidation.
thiamine-independent enzymes ribose phosphate
isomerase and ribulose phosphate-3-epimerase.8
Calculation and interpretation of
the ETKAC
Calculation of the ETKAC in erythrocyte lysates
involves: (1) measurement of the basal activ-
ity of ETK; and (2) measurement of activated
or stimulated ETK activity by the addition of
exogenous excess ThDP. The basal test represents
the active holo-transketolase activity. Addition of
exogenous ThDP activates apo-transketolase and
the stimulated activity represents the activity of
both the (now-activated) apo-transketolase and
holo-transketolase. Takeuchi et al. demonstrated in
experiments with apo-transketolase enzymes that
the ETKAC reflects the degree of saturation of ETK
with ThDP.12
The results of the basal and stimulated activities
are commonly presented as a ratio or activity coef-
ficient, the ETKAC calculated as (stimulated activ-
ity)/(basal activity). Alternatively, results may be
presented as a percentage (% activation = (ETKAC
× 100) – 100; also known as the thiamine pyrophos-
phate effect (TPPE)).
In thiamine sufficiency, addition of exogenous
ThDP will make little difference to the enzyme
activity and hence an ETKAC close to 1 will be
obtained. In thiamine insufficiency or deficiency,
the addition of exogenous ThDP has a progressively
greater effect on ETKAC, which provides a contin-
uum of thiamine status.13
Although there is no international consensus on
cutoffs, the commonly used threshold for risk of
deficiency is an ETKACof>1.25.13,14 An ETKACof
<1.15 indicates sufficiency and values between 1.15
and 1.25 suggest a low risk of clinical deficiency.13
Others have suggested values of ≥1.2 indicate
deficiency.15 Beriberi is typically associated with
ETKAC values >1.4.2
The use of ETKAC rather than absolute mea-
sures of ETK activity is preferred for three main
reasons: (1) the between-subject variation in basal
activity is large; (2) it is assumed, but not certain,
that apoenzyme levels are not affected by vitamin
deficiencies;5 and (3) it reduces the need for the
precise definition of assay conditions (e.g., optical
path length), which are critical to calculate absolute
enzyme activities.16 Others have suggested using
combinations of the stimulated ETK activity and the
ETKAC in interpretation.17
However, the use of basal ETK activity rather
than ETKAC has also been recommended, par-
ticularly for the assessment of thiamine status in
infants due to potential low levels of apoenzyme
caused by long-term low exposure to thiamine.18 A
recent study of children and adults found that while
both basal and ETKAC correlated with erythro-
cyte ThDP, the correlation was stronger for basal
activity.19 Basal (or activated ETK) activity needs to
be expressed per mass unit of hemoglobin, and it
is necessary to measure the hemoglobin concentra-
tion in the same lysate as used for the ETK activity
assay. In addition, it is necessary to calculate the fac-
tor needed to convert rate to activity.
Recommended sample type
Washed erythrocytes are the recommended sample
type. Leukocytes have relatively large amounts of
thiamine, and transketolase activity can, therefore,
be considerably higher in whole blood compared
with erythrocytes.8,20 The use of leukocytes21,22 to
assess transketolase activity has been reported but
has not been applied routinely, possibly because the
shorter half-life of leukocytes compared with ery-
throcytes would result in a biomarker of thiamine
status that is only short term.
The use of whole blood, a more convenient sam-
ple compared with washed erythrocytes, has also
been considered. While transketolase activity was
higher in whole blood, the transketolase activity
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Figure 2. Deming regression of ETKACmeasured in erythro-
cyte hemolysates collected in either ETDA or lithium heparin
(LH) blood tubes from 15 adults. Open circles, observed data
points; solid line, regression line; dashed line, line of equality.
Slope (95% CI) = 0.88 (0.37–1.39); intercept (95% CI) = 0.26
(−0.44 to 0.68).
coefficient was similar between whole blood and
erythrocyte hemolysates.20,23 However, there are
concerns around the use of whole blood, partly due
to between-person variability in leukocyte count,
particularly in clinical conditions that may impact
leukocyte number.24
Whole blood collected in blood tubes containing
either lithium heparin (LH) or ethylenediaminete-
traacetic acid (EDTA) anticoagulant can be used as
the starting sample for the preparation of washed
erythrocytes. Agreement in our own laboratory
between the two sample types is shown in Figure 2.
Sample stability
A small number of studies have investigated the sta-
bility of ETK activity and ETKAC across a number
of analytical stages, including in whole blood and
hemolysates, and at a range of temperatures from
refrigeration at 4 °C to frozen storage at −20 and
−70 °C, possibly reflecting the availability of cold
storage in different clinical and field site settings.
Whole blood
In whole blood kept at 4 °C or at room temperature,
the ETKAC was stable for up to 24 h, decreasing
thereafter;25,26 however, basal activity was report-
edly stable for up to 4 days.25
In our laboratory, whole blood samples from 15
participants kept at 4 °C were also observed to be
stable for 24 h, with no significant change in the
ETKAC observed in LH-treated whole blood (%
geometric mean change (95% confidence interval):
−0.3 (−2 to 2)) or in EDTA-treated whole blood
(−1 (−3 to 1)), and they showed good agreement
(Fig. 3).
Washed erythrocytes
Puxty et al. observed greater deterioration of the
ETKAC after storage of washed erythrocytes at
−20 °C in participants in an insufficient group
(ETKAC > 1.15) group than in a sufficient group
(ETKAC < 1.15), and they speculate this may
be due to the stability of different isoenzymes. In
the sufficient group, samples were stable for up
to 14 days at −20 °C but for only 4 days in the
insufficient group.26 Washed erythrocytes stored at
4 °C were stable for less than 2 days.26 Other stud-
ies observed no consistent change over time in basal
and stimulated activity.9
Hemolysates
Hemolysates can be kept frozen at −20 °C for at
least 4 weeks; however, caution should be paid to
the number of freeze-thaw cycles since reports sug-
gest that significant decreases in enzyme activity
can occur after two freeze-thaw cycles.8 Another
study showed a decrease of 7% in the ETKAC
in hemolysates analyzed after freezing at −18 °C
for 2 weeks compared with fresh samples.27 As
with washed erythrocytes, samples kept at −70 °C
remained stable for at least 2 months.25 In our own
laboratory, we observed a less than 1% change in
the ETKAC in a set of 59 hemolysates stored at
Figure 3. Deming regression of ETKACmeasured in erythro-
cyte hemolysates prepared from LH and EDTA whole blood
collected from 15 adults and processed within 2 h of collection
or after refrigeration for 24 hours. Dashed line is the line of
equality.
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ETKAC, first analysis
Figure 4. Deming regression of repeat analysis of erythrocyte
hemolysates after storage for 6months at−70 °C. Open circles,
observed data points; solid line, regression line; dashed line,
line of equality. Slope (95% CI) = 1.06 (0.92–1.20); intercept
(95% CI) = −0.07 (−0.24 to 0.09) (n = 59).
−70 °C for 6 months and excellent agreement
across a range of EKTACs (Fig. 4). Enzyme activities
reportedly remain stable at −70 °C for over 1 year.2
Storage of washed erythrocytes and hemolysates at
−70 °C or below is recommended.16
Assay and individual variability
Analytical variability
Our routine method includes three internal QC
materials with ETKAC (mean (SD)) of 1.07 (0.03),
1.15 (0.05), and 1.18 (0.05) and corresponding
between-batch %CVs of 3.1, 3.9, and 4.1% (n= 25).
Targets of <5% are recommended.
Within-individual variation
A study from 1990 reported within-individual vari-
ation of basal and activated transketolase activity
between 3% and 6% measured in 20 samples col-
lected from each of four individuals over 60 days on
a constant diet.28
Between-individual
ETKAC data from the UKNational Diet and Nutri-
tion Survey (NDNS) Rolling Programme (Years 7–8
(2014–2016))29 are presented in Table 1 and show
the range of values in a largely thiamine-replete
population. Between-individual CV is around 5%.
The 2.5th–97.5th percentile range in the UK popu-
lation based on the NDNS Rolling Programme data
for Years 1–8, using the ETKAC method described
herein, is 1.01–1.21.
Limitations and other factors
Genetic differences leading to different transketo-
lase isoforms that may have different activities or
stabilities30 or be associated with the manifesta-
tion of thiamine deficiency in Wernicke–Korsakoff
syndrome have been suggested.30,31 However, other
studies have found no evidence for isoforms or dis-
ease associations and suggest that earlier observa-
tions were due to the methodologies used.32–36
A venous whole blood sample is required for
the determination of ETKAC (and whole blood
ThDP). While a venous blood sample is a common
sample type, collection and processing of blood
samples in the field or limited-resource settings
present a number of challenges, including labora-
tory infrastructure for washing of erythrocytes and
cold storage. Capillary blood sampling and dried
blood spots (DBSs) provide amore convenient sam-
ple. Recently, Huang et al. described a DBS method
for ThDP that showed a high degree of correlation
with whole blood results (r = 0.964; P < 0.0001),
although ThDP in DBSs was not stable at room
temperature.37 Further work is required to deter-
mine the feasibility of measuring ETKAC in whole
blood as either a venous sample or a DBS.
The impact of clinically observed thiamine
deficiency, ThDP concentration, their effect on
transketolase enzyme, and consequences for inter-
pretation of transketolase activity have been a
topic of discussion for many years.17,38 It has been
suggested that liver disease may directly affect
apo-transketolase concentration, causing appar-
ently normal ETKAC in the presence of clinical
symptoms of thiamine deficiency. However, other
studies posit that the decrease in apo-transketolase
is a response to thiamine deficiency.17,38 Either
way, chronic thiamine deficiency may cause loss
of apo-transketolase and evidence suggests that
this is caused by an effect on synthesis rather than
catabolism of transketolase.39 The impact of this
effect on interpretation of the EKTAC is, however,
uncertain. Price et al. observed a lower activation
after in vitro stimulation of ETK compared with in
vivo activity following thiamine supplementation
that may be related to irreversible inactivation
of the enzyme in vitro.40 Thus, observations in
vitro may not represent the in vivo situation.
Clinical conditions, for example, certain anemias
or diseases that affect erythrocyte cell survival
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Table 1. ETKAC inUKpopulation estimated from theUKNational Diet andNutrition Survey Rolling Programme,
Years 7 and 8 (2014−2016)
Risk of deficiency, %a







Children 4−10 years old 1.10 (0.052) 101 80 20 0
Children 11−18 years old 1.12 (0.052) 164 68 32 0
Adults 19−64 years old 1.11 (0.052) 513 73 26 1
Adults 65+ years old 1.10 (0.062) 153 80 19 1
aPercentages are weighted to provide risk of deficiency estimates for the UK population.
time and the age distribution, may also affect the
interpretation of ETKAC. Holo-transketolase
enzyme concentration is lower in older than
younger erythrocytes41 and as holo-transketolase
decreases, there is a consequent increase in the
ETKAC.26,41
Conclusions
The ETKAC assay provides an indirect, func-
tional measure of thiamine status. Perceived lim-
itations of the assay include relatively poor pre-
cision, lack of standardization, instability of the
transketolase enzyme, and lack of consensus about
cutoffs for deficiency.42 However, these limitations
equally apply to other assays of thiamine status,
such as whole blood ThDP. ETKAC has advan-
tages over methods for the direct measurement
of ThDP, including relative ease and the require-
ment for less specialized equipment, making the
assay potentially more affordable and sustainable.
Furthermore, ETKAC provides a potentially bet-
ter marker of long-term thiamine status that is less
affected than ThDP by acute changes in thiamine
intake.43
In this paper, we provide a detailed protocol for
the measurement of ETK activity that can be used
as a foundation for assay harmonization. There is
also a need to develop an external quality assur-
ance scheme to provide for the independent mon-
itoring and assessment of laboratory performance.
The establishment of a network of international lab-
oratories willing to share samples for an interlab-
oratory comparison could provide a first step in
the development of an external quality assurance
scheme. The difficulty of obtaining blood samples
in sufficient volume from thiamine-deficient indi-
viduals results in a lack of quality control materi-
als that include the thiamine-deficient range. There-
fore, there is a need to develop quality control and
reference materials with consensus values spanning
both sufficiency and deficiency, which can be sup-
plied to laboratories in order to monitor, under-
stand, and standardize assay performance.
Improvements in harmonization will also pro-
vide opportunity for investigating outstanding
questions related to thiamine physiology and
EKTAC assays, including the establishment of cut-
offs for deficiency, characterizing agreement with
other markers of thiamine status (e.g., ThDP), and
to better understand conditions where interpreta-
tion of ETKAC may be confounded.
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